Cargando…
Targeting SHP2 with an Active Site Inhibitor Blocks Signaling and Breast Cancer Cell Phenotypes
[Image: see text] The Src homology phosphotyrosyl phosphatase 2 (SHP2) is an oncogenic protein for which targeted therapies are being sought. In line with this idea, we have previously reported the development of a specific active site inhibitor named CNBDA that showed effectivity in suppressing the...
Autores principales: | Lade, Dhanaji M., Agazie, Yehenew M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2023
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10591299/ https://www.ncbi.nlm.nih.gov/pubmed/37876496 http://dx.doi.org/10.1021/acsbiomedchemau.3c00024 |
Ejemplares similares
-
SHP2 Potentiates the Oncogenic Activity of β-Catenin to Promote Triple-Negative Breast Cancer
por: Martin, Elisha, et al.
Publicado: (2021) -
Novel Small-Molecule Inhibitor for the Oncogenic Tyrosine
Phosphatase SHP2 with Anti-Breast Cancer Cell Effects
por: Hartman, Zachary, et al.
Publicado: (2020) -
Inhibition of SHP2 in basal-like and triple-negative breast cells induces basal-to-luminal transition, hormone dependency, and sensitivity to anti-hormone treatment
por: Zhao, Hua, et al.
Publicado: (2015) -
SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer
por: Matalkah, Fatimah, et al.
Publicado: (2016) -
Conditional knockout of SHP2 in ErbB2 transgenic mice or inhibition in HER2-amplified breast cancer cell lines blocks oncogene expression and tumorigenesis
por: Zhao, Hua, et al.
Publicado: (2018)